Compare Manulife Financial Corporation (MFC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Manulife Financial Corporation trades at $42.93 (market cap $71.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Manulife Financial Corporation is far larger — about 9.5× Spyre Therapeutics Inc. Common Stock's market cap, and Manulife Financial Corporation pays a 3.15% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 120 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MFC | SYRE | |
|---|---|---|
Market Cap | $71.31B | $7.52B |
Volume | 1,535,090 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $44.77 | $108.92 |
52-Week Low | $31.64 | $22.18 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $66.58B | $6.52B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.10, up 0.56% today, with a neutral technical signal and bullish moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7% and a P/E of 16.73. Recent news includes a new Chief Marketing Officer appointment and strong institutional investments, such as Bank of America's $145.18 million stake.
The outlook is positive with analyst consensus at Buy (57.14%) and a price target of $34.24, though below the current price. Risks include competitive pressures and debt levels, but earnings beats and dividend payments support stability. Growth is driven by Asia expansion and reinsurance deals, yet valuation premiums may limit near-term upside.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
